Ocular Therapeutix

Today, we announced positive results from the landmark SOL-1 Phase 3 superiority trial in wet AMD, an important step forward as we aim to reduce the treatment burden, with the data presentation taking place at Macula Society this month. Learn more: ow.ly/svKn50YgYXM

Tune in for the @RBC Ophthalmology Conference tomorrow, where Ocular’s Executive Chairman, President, and CEO Pravin Dugel, MD, will lead a fireside chat to discuss recent developments in retina. Learn more: ow.ly/lqZo50YrB3h #RetinaRedefined

At Macula Society, retina specialists reflected on one of the biggest challenges in wet AMD care: the high treatment burden of frequent injections. At Ocular, we’re aiming to redefine the retina experience for patients. Learn more: ow.ly/NoNM50Ys8a7 #RetinaOnRecord

We’re excited for the @CitizensBank Life Sciences Conference tomorrow! Ocular’s Executive Chairman, President, and CEO Pravin Dugel, MD, will join a fireside chat to share updates as we advance our mission to redefine the retina experience. Learn more: ow.ly/6bgZ50YrAZF

It was an exciting moment for retina innovation at Macula Society with the first-time data presentation of our landmark SOL-1 Phase 3 superiority trial in wet AMD. Check out the full, unedited presentation: bit.ly/4bk7isj #MaculaSociety

We’re gearing up to participate in several investor conferences next month, where we’ll discuss key updates across our registrational programs, including the latest on our landmark SOL-1 Phase 3 superiority trial in wet age-related macular degeneration. ow.ly/YpQp50YkXbx

We're excited for Macula Society this week, where first-time data from our Phase 3 SOL-1 superiority trial in wet AMD will be presented. We will also host an investor webcast at 7:30am ET on Monday, March 2, to discuss the presentations.​ Learn more: ow.ly/38yi50Yky5P

The first-time presentation of positive data from our landmark SOL-1 Phase 3 superiority trial in wet age-related macular degeneration will take place at Macula Society, alongside an update on our HELIOS program in non-proliferative diabetic retinopathy.​ #MaculaSociety

Today, we shared our Q4 and 2025 earnings, demonstrating continued progress on our mission to redefine the retina experience. We also announced our expected data presentation for SOL-1 and updated timing for SOL-R topline data results. ow.ly/sVao50Y9xxf

We’re excited to announce plans to accelerate a New Drug Application (NDA) for the treatment of wet age-related macular degeneration (AMD), pending positive results from SOL-1. Learn more: ow.ly/j8sl50XFZeE #RetinaRedefined

Excited to engage with forward-thinkers on the future of retina care at @Piper_Sandler’s Healthcare Conference. Join our Dec. 3 fireside chat with CEO Pravin Dugel to discuss our mission to redefine the retina experience. #RetinaRedefined

Ocular is excited to announce the initiation of our HELIOS phase 3 trial for non-proliferative diabetic retinopathy, a leading cause of vision loss in working-age adults, as we advance our mission to redefine the retina experience. ​ Learn more: ow.ly/NnBZ50XwNrf

We’re excited to attend the @Jefferies and @Piper_Sandler’s Annual Healthcare Conferences, where we’ll connect with fellow industry leaders, and discuss what’s next as we work to redefine the retina experience. Learn more: ow.ly/eFNW50XquYi #RetinaRedefined

Today, we announced our Q3 2025 earnings and that the SOL-R study has achieved its target randomization, reflecting exceptional execution in our clinical trials and a significant step toward redefining the retina experience.​ Learn more: ow.ly/xGlh50XmBbY​ #RetinaRedefined

Don’t miss our Q3 earning on November 4, we’ll share key financial outcomes as well as the latest updates from our wet age-related macular degeneration and planned diabetic retinopathy trials. Learn more: ow.ly/aErJ50XiZeJ #RetinaRedefined

Great to connect with the retina community and other industry leaders to share our commitment to redefining the retina experience and improving outcomes for patients at @aao_ophth’s Annual Meeting. Learn more: ow.ly/HUFl50XhasP #AAO2025 #RetinaRedefined

@Eyecelerator @ AAO 2025 provided a valuable forum for discussions on innovative treatment strategies for retinal disease. We’re grateful for the conversations that continue to shape progress in retina. Learn more: ow.ly/8ffQ50XfK6t #Eyecelerator #RetinaRedefined

Kicking off the @aao_ophth Annual Meeting! Looking forward to impactful discussions with the retina community as we drive meaningful progress in retinal disease care.​ Join us at booth 2701 to learn more about our mission to redefine the retina experience. ​ #AAO2025

Catch up with our team at the @aao_ophth Annual Meeting this week in Orlando. ​ Excited to share how we’re working to redefine treatments for patients with retinal disease, including wet age-related macular degeneration. ​ #AAO2025 #RetinaRedefined

Looking forward to an impactful series of meetings as Innovate Retina, @Eyecelerator, and @aao_ophth showcase advances in retina care. Joining these events reinforces our commitment to redefining the retina experience. Learn more: ow.ly/SQFS50X7Hp6 #RetinaRedefined